XIAOMI-W
01810
BABA-W
09988
ALI HEALTH
00241
KUAISHOU-W
01024
BIDU-SW
09888
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|
Turnover | 36.10%150.82M | 45.86%253.23M | 54.29%110.81M | 14.66%173.61M | --71.82M | 101.13%151.4M | 45.15%75.28M | --51.86M |
Operating income | 36.10%150.82M | 45.86%253.23M | 54.29%110.81M | 14.66%173.61M | 71.82M | 101.13%151.4M | 45.15%75.28M | 51.86M |
Cost of sales | ---- | ---- | ---- | ---- | ---- | -107.89%-80.52M | -39.43%-38.73M | ---27.78M |
Operating expenses | -25.97%-67.02M | -39.08%-127.49M | -32.83%-53.2M | -13.85%-91.67M | -40.05M | -107.89%-80.52M | -39.43%-38.73M | -27.78M |
Gross profit | 45.45%83.8M | 53.45%125.73M | 81.32%57.61M | 15.59%81.94M | 31.77M | 93.97%70.88M | 51.74%36.54M | 24.08M |
Selling expenses | -50.20%-103.52M | -80.03%-210.09M | -76.72%-68.92M | -123.32%-116.7M | ---39M | 5.09%-52.26M | -103.90%-55.06M | ---27M |
Administrative expenses | 12.68%-19.7M | -9.79%-45.6M | -57.54%-22.57M | -0.13%-41.53M | ---14.32M | 9.35%-41.48M | -36.12%-45.76M | ---33.62M |
Research and development expenses | -7.91%-34.55M | -14.75%-70.1M | -30.23%-32.02M | -69.29%-61.09M | ---24.59M | 56.00%-36.08M | -63.82%-82.01M | ---50.06M |
Profit from asset sales | ---- | ---- | ---- | ---8.31K | ---- | ---- | ---- | ---- |
Revaluation surplus | --140.41K | ---15.62K | ---- | ---- | ---- | ---- | ---- | ---- |
-Changes in the fair value of other assets | --140.41K | ---15.62K | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provision | -55.77%-4.03M | 8.72%-4.51M | -388.64%-2.58M | -302.24%-4.94M | ---529K | -553.72%-1.23M | 55.56%-188K | ---423K |
-Other impairment is provision | -55.77%-4.03M | 8.72%-4.51M | -388.64%-2.58M | -302.24%-4.94M | ---529K | -553.72%-1.23M | 55.56%-188K | ---423K |
Special items of operating profit | 595.41%6.76M | -53.19%10.59M | -34.77%971.96K | 87.99%22.61M | --1.49M | -52.88%12.03M | 192.92%25.53M | --8.72M |
Operating profit | -6.80%-72.82M | -62.29%-195.31M | -49.23%-68.18M | -150.02%-120.35M | -45.69M | 60.20%-48.14M | -54.45%-120.94M | -78.3M |
Financing cost | -29.16%35.1M | -12.14%75.04M | 31.06%49.55M | 502,458.72%85.4M | --37.81M | 94.48%-17K | 0.96%-308K | ---311K |
Special items of earning before tax | -2.01%-33.81K | -4,796.74%-4.58M | 47.39%-33.14K | ---93.53K | ---63K | ---- | ---- | ---- |
Earning before tax | -102.27%-37.75M | -256.30%-124.85M | -134.97%-18.66M | 27.23%-35.04M | -7.94M | 60.29%-48.15M | -54.23%-121.25M | -78.61M |
Tax | --11.74K | -10,755.18%-163.62K | ---- | ---1.51K | ---- | ---- | ---- | ---- |
After-tax profit from continuing operations | -102.21%-37.74M | -256.75%-125.02M | -134.97%-18.66M | 27.23%-35.04M | -7.94M | 60.29%-48.15M | -54.23%-121.25M | -78.61M |
Earning after tax | -102.21%-37.74M | -256.75%-125.02M | -134.97%-18.66M | 27.23%-35.04M | -7.94M | 60.29%-48.15M | -54.23%-121.25M | -78.61M |
Minority profit | ---- | ---- | ---- | ---- | ---- | ---- | ---241K | ---- |
Profit attributable to shareholders | -102.21%-37.74M | -256.75%-125.02M | -134.97%-18.66M | 27.23%-35.04M | -7.94M | 60.21%-48.15M | -53.93%-121.01M | -78.61M |
Basic earnings per share | -125.00%-0.09 | -262.50%-0.29 | -100.00%-0.04 | 38.46%-0.08 | -0.02 | 66.67%-0.13 | -39.29%-0.39 | -0.28 |
Diluted earnings per share | -125.00%-0.09 | -262.50%-0.29 | -100.00%-0.04 | 38.46%-0.08 | -0.02 | 66.67%-0.13 | -39.29%-0.39 | -0.28 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.